Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 569 followers
Latest posts
Last updated 2 days ago
Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer
2 days ago
Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase...
U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments
5 days ago
If approved, Enspryng would be the first and only disease-modifying therapy for...
Reminder: Invitation to Roche Pharma Day 2026
12 days ago
The Roche Investor Relations team would like to invite you to the...
Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer’s disease assessment across primary and specialty care
22 days ago
First and only FDA-cleared, single-biomarker blood test supporting both rule-in and rule-out...
Invitation to Roche Pharma Day 2026
about 1 month ago
The Roche Investor Relations team would like to invite you to the...
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
about 1 month ago
Dear Investor, Please find attached a press release from our partner Nurix...
CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
about 2 months ago
Susvimo is the first and only continuous delivery treatment that offers an...
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc
about 2 months ago
Group sales were +6% at constant exchange rates (CER)1, -2% when reported...
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc
about 2 months ago
Group sales were +6% at constant exchange rates (CER)1, -2% when reported...
Reminder: Invitation to Roche’s Half Year Results 2026 Presentation
2 months ago
Roche will publish its Half Year Results of 2026 prior to the...
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy
2 months ago
Priority Review decision is based on phase III MAJESTY results, where Gazyva/Gazyvaro...
Roche receives CE Mark for blood test to identify tuberculosis infection
2 months ago
The Elecsys IGRA TB test expands global access to tuberculosis infection testing...